Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06.

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).

Here's What to Expect From Biogen's Next Earnings Report

Here's What to Expect From Biogen's Next Earnings Report

Biogen is expected to release its fiscal second-quarter earnings later this month, and analysts project a double-digit profit decline.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Can Biogen Save Even More Kids With This New Drug?

Biogen said Wednesday its experimental treatment helped children with SMA even after they received an approved gene therapy from Novartis.

Investors Business Daily

Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?

Biogen stock traded sideways Thursday after the company beat first-quarter expectations, including strong sales for two newcomer drugs.

Investors Business Daily

Earnings Preview: What To Expect From Biogen's Report

Biogen is poised to announce its first-quarter results next month, and analysts predict a single-digit dip in the company’s bottom-line figure.

European regulators OK Alzheimer's treatment Leqembi after initial doubts

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Wall Street expects both of these biotech stocks to soar over 200% in the next 12 months.

How Is Biogen's Stock Performance Compared to Other Biotech Stocks?

How Is Biogen's Stock Performance Compared to Other Biotech Stocks?

Despite Biogen's underperformance compared to other biotech stocks over the past year, analysts remain moderately optimistic about its future prospects.

Do You Own 15 Stocks Morningstar Calls The Top 'Wealth Destroyers?'

Do You Own 15 Stocks Morningstar Calls The Top 'Wealth Destroyers?'

The S&P 500 can generate massive wealth. But stocks can decimate portfolio values, too.

Investors Business Daily

Biogen Stock Outlook: Is Wall Street Bullish or Bearish?

Biogen Stock Outlook: Is Wall Street Bullish or Bearish?

Biogen has lagged well behind the broader market over the past year, yet analysts maintain a fairly optimistic outlook on its future performance.

2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

Biogen Stock Is Mutating Into a Value Play

Biogen Stock Is Mutating Into a Value Play

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

Stocks Settle Mixed as Chip Stock Strength Lifts the Nasdaq

Stocks Settle Mixed as Chip Stock Strength Lifts the Nasdaq

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.50%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.12%. March E-mini S&P futures (ESH25 ) are down by -0.29%, and March E-mini Nasdaq...

Get all your
news in one place.

100’s of premium titles.
One news app.

Stocks Tumble as Sticky US Inflation Keeps Fed on Hold

The S&P 500 Index ($SPX ) (SPY ) today is down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.32%. March E-mini S&P futures (ESH25 ) are down by -0.48%, and March E-mini Nasdaq...

Stocks Sink and Bond Yields Spike on Strong CPI

The S&P 500 Index ($SPX ) (SPY ) today is down -0.91%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.92%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.89%. March E-mini S&P futures (ESH25 ) are down by -0.87%, and March E-mini Nasdaq...

Investors Business Daily

Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat

Biogen stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.

Biogen's Quarterly Earnings Preview: What You Need to Know

Biogen is scheduled to release its fourth-quarter earnings next month, and analysts are forecasting a double-digit increase in its bottom line.

Get all your
news in one place.

100’s of premium titles.
One news app.

Biogen Stock: Is BIIB Underperforming the Healthcare Sector?

Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential.

Investors Business Daily

Analysts Predict These Will Be Next Year's Top 10 Stocks

Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025.

Assessing Biogen: Insights From 19 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months.

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

The Independent UK

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

Investors Business Daily

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review

The stock market retreated this week amid earnings from Microsoft, Amazon, Meta, Apple, Google and many more, along with preelection jitters.

Investors Business Daily

Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.

Biogen stock dipped Wednesday despite an unexpected boost from its new Alzheimer's drug, Leqembi, and an earnings guidance hike.

People

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Multiple Sclerosis

Places

294,094 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play